Consensus $1.01B. The Company expects 2023 gross margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $540 million to $580 million; research and development costs to be approximately $325 million to $345 million; and net cash consumption to be approximately $300 million to $325 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTRA:
- Natera files patent infringement suit against NeoGenomics
- Natera completes enrollment in ALTAIR trial
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
- CareDx announces district court upholds March 2022 jury verdict against Natera
- Natera announces ruling in favor of the company in CareDx false advertising case